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Background: In this study, we investigate the expression of markers of angiogenesis and microves-
sel density (MVD) in cases of microcystic, elongated and fragmented (MELF) pattern, with its prog-
nostic role in the survival of endometrioid endometrial adenocarcinomas (EA) patients. Methods: In 
this study, 100 cases of EA, 49 cases with MELF pattern and 51 without, were immunohistochemi-
cally stained for galectin-1, vascular endothelial growth factor (VEGF), and MVD. Morphometry 
and statistical (univariate and multivariate) analyses were performed to assess overall survival (OS) 
and disease-free survival. Results: The expression of VEGF (p < .001) and galectin-1 (p < .001), as 
well as MVD area (p < .001) and number of vessels/mm2 (p < .050), were significantly higher in the 
+MELF pattern group compared to the –MELF group. A low negative correlation between MELF-
pattern and the number of days of survival (p < .001, r = –0.47) was also found. A low positive cor-
relation of MELF-pattern with galectin-1 expression (p < .001, r = 0.39), area of vessels/mm2 (p < 
.001, r = 0.36), outcome of EA (p < .001, r = 0.42) and VEGF expression (p < .001, r = 0.39) suggests 
potential pathological relevance of these factors in the prognosis of EA. A univariate survival analysis 
indicated a role for all parameters of survival. Multivariate Cox proportional hazard regression 
analysis revealed that only area of vessels/mm2 (hazard ratio [HR], 1.018; 95% confidence interval 
[CI], 1.002 to 1.033), galectin-1 (HR, 1.049; 95% CI, 1.025 to 1.074) and VEGF (HR, 1.049; 95% 
CI, 1.022 to 1.077) play key roles in OS. Conclusions: This study reports an increase in MVD, VEGF 
and galectin-1 expression in EA with MELF pattern and suggests that MELF pattern, along with 
the angiogenic profile, may be a prognostic factor in EA.
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▒ ORIGINAL ARTICLE ▒
Although most early-stage endometrioid endometrial adeno-
carcinomas (EA) have an excellent prognosis, a minority of low-
grade disease cases may have an aggressive clinical course.1-4 EAs 
are histologically heterogeneous with myometrial invasion char-
acterized by a microcystic, elongated and fragmented (MELF) 
pattern surrounded by myxoid and inflamed stroma. MELF pat-
tern was first described by Murray et al. in 2003,5 but only a 
few studies since have reported on the biological potential of 
this histopathological lesion.
Most published studies have focused on the clinicopathologi-
cal and immunohistochemical parameters of the cancer micro-
environment in relation to the MELF pattern. However, the role 
of microvessels and angiogenic factors such as galectin-1 and vascu-
lar endothelial growth factor (VEGF) in the MELF pattern has not 
been described. Furthermore, the role of the specific fibromyxoid 
stromal changes in the prognosis of survival of patients with EA 
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remains unclear.6 The MELF pattern is known to be associated 
with lymphovascular invasion and lymph node metastasis, but 
no significant role of this lesion in relation to patient survival has 
been investigated.7,8 However, other studies have shown that the 
MELF pattern may play a negative role in the survival of patients 
suffering from EA.9,10 
In this study, we hypothesize that there is a significant associa-
tion between the MELF pattern and microvessel density (MVD), 
as well as angiogenic factors such as VEGF and galectin-1, which 
play key roles in determining poor survival of patients. Therefore, 
we investigated the presence of galectin-1, VEGF, and microves-
sels in the tumor microenvironment using an immunohisto-
chemical technique. We also analyzed the aforementioned asso-
ciation and report for the first time that these criteria may be used 
as possible prognostic factors of EA.
MATERIALS AND METHODS
Patients 
This prospective study involved women with EA who were 
treated in 2015 in the Grodno and Gomel regions in the Republic 
of Belarus. The inclusion criteria for the study were a presence of 
stage I-III EA (International Federation of Gynecology and Ob-
stetrics [FIGO], 2009), hysterectomy and an absence of malig-
nant tumors in other locations during life. EA stage IV (FIGO, 
2009), Lynch syndrome, palliative treatment, a presence of syn-
chronous and metachronous malignancies and the presence of 
other specific growth patterns of EA were the exclusion criteria 
for this study.11
The presence of the MELF pattern was confirmed indepen-
dently by three pathologists (D.A.Z., S.L.A., and M.G.Z.). The 
pattern was identified by the presence of elongated, dilated (mi-
crocystic) and disrupted invasive tumor glands with peri-glandular 
fibromyxoid stromal reactions and single invasive tumor cells in 
the stroma around the pattern (Fig. 1). 
A total of 100 out of 424 cases of EA during the study period 
were determined to be eligible for inclusion in this study. Patients 
were divided into two groups according to the presence or absence 
of MELF pattern. The first group included 49 subjects who had 
EA with stroma-specific MELF pattern (MELF positive group). 
The second group consisted of 51 patients who had no MELF 
pattern changes in the stroma (MELF negative group). The obser-
vation period was 36 months. All patients received treatment 
according to the National Protocols of Diagnostics and Treat-
ment of Oncological Diseases of the Republic of Belarus. Clinico-
pathological characteristics of patients are presented in Table 1.
Immunohistochemistry
Immunohistochemical study was undertaken at the Gomel 
State Medical University, Belarus, with informed consent from 
all patients and with ethical approval from the Institutional Re-
view Board (Gomel State Medical University), Gomel, Belarus.
The primary antibodies used in this study were ready-to-use 
monoclonal mouse Gal-1 (Abcam, Cambridge, UK), anti-VEGF 
(Diagnostic Biosystems, Pleasanton, CA, USA), and anti-CD34 
(Diagnostic Biosystems). An UnoVue HRP/DAB Detection 
System (Diagnostic Biosystems) was used for primary antibody 
visualization. 
Table 1. Clinicopathological characteristics of the patients
Characteristic
MELF-positive 
group (n = 49)
MELF-negative 
group (n = 51)
p-value
Age (yr) 64.2 ± 4.8 63.8 ± 5.2    .982a
FIGO stage    .942b
I 12 11
II 23 25
III 14 15
Tumor grade    .855b
G1 20 22
G2 23 22
G3   6   7
Lymphovascular invasion    .115c
Present 29 22
Absent 20 29
Myometrial invasion (%)  > .99c
< 50 10   9
> 50 39 42
MELF, microcystic, elongated and fragmented; FIGO, International Federa-
tion of Gynecology and Obstetrics. 
aMann-Whitney U test; bKruskal-Wallis test; cFisher’s two-tailed exact test.
Fig. 1. Specific microcystic, elongated and fragmented pattern 
changes: endometrioid carcinoma showing eosinophilic glands with 
microcystic transformation embedded in fibromyxoid stroma and 
cancer cell complexes with some areas resembling vascular invasion.
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The method employed in this study has been described in our 
previous work.10,11 Briefly, sections of tissue (4 to 5 µm thick) 
were deparaffinized and washed with distilled water. Antigen 
retrieval was performed using a microwave. The sections were then 
allowed to cool and endogenous peroxidase blocking was per-
formed in 5% hydrogen peroxide. Blocking of nonspecific anti-
body binding was carried out in 5% casein. Sections were washed 
and incubated in a moist chamber at room temperature with 
corresponding primary antibodies followed by incubation with 
anti-mouse horseradish peroxidase secondary antibodies. The 
reaction product was visualized after 3,3-diaminobenzidine (DAB) 
staining for 5 minutes followed by Mayer’s hematoxylin coun-
terstaining.10,11
Morphometry
The morphometrical analysis was carried out using package 
NIS-Elements. The tumor invasion zone was photographed using 
a microscope (Nikon Eclipse 50i, Nikon, Tokyo, Japan) with a 
digital camera (DS-Fi2) in 5 non-overlapping high-power fields 
(HPF; ×400 magnification) of maximum expression for each 
marker. Expression of VEGF and galectin-1 in cell counting was 
analyzed using the function “measure.” The number of positive 
cells was expressed as a percentage of the total number of cells 
in the epithelial component of the tumor.
MVD was presented as the area and number of vessels per 
mm2. The number of vessels was counted in 5 non-overlapping 
HPF in areas of “hot spots” and inverted into mm2 using the for-
mula:
N = Xˉn × 1000000/118947.07
where N = number of vessels per mm2; (Xˉ)n = mean number of 
vessels; and 118947,07 = area of one HPF (µm2).
The area of the vessels was counted in 5 non-overlapping HPFs 
in regions of “hot spots” using the function “area.” Area of vessels 
after the count was inverted into mm2 using the formula: 
S = Xˉs × 1000000/118947.07 
where S = area of vessels per 1 mm2; Xˉs = mean area of vessels; 
and 118947,07 = area of one HPF (µm2).
Statistical analysis
Power analysis (power = 80%, α = 0.05) during the pilot study, 
in which parameters were received from four cases with MELF 
pattern and four without the pattern in 5 HPF, revealed that 
the minimum number of subjects should be 18. The data were 
presented as the median, lower and upper quartiles. The Mann-
Whitney test was used for comparing the study groups based on 
the evaluated criteria. The Spearman correlation test with Chad-
dock scale was used to perform correlation analysis. The hazard 
ratio (HR) with a 95% confidence interval (95% CI) was deter-
mined for overall survival (OS) and disease-free survival (DFS) 
using univariate and multivariate Cox proportional hazards regres-
sion models. A p < 0.05 was considered statistically significant. 
GraphPad Prism v.7.29 (GraphPad Software Inc., San Diego, 
CA, USA) and R Software v 3.4.0 were used for analysis (R Foun-
dation for Statistical Computing, Vienna, Austria). 
RESULTS
Galectin-1 expression in EA tissue
Galectin-1 was observed to be diffusely expressed by epithe-
lial cancer cells, stromal cancer cells and vessels in both groups. 
However, the intensity of the expression of this marker in the 
MELF negative group was significantly lower (p < .001) than the 
MELF-positive group (Fig. 2A, B). The median galectin-1 expres-
sion in the MELF pattern-positive and -negative groups were 
78.6 % (40.1%–88.3%) and 34.2% (24.4%–55.5%), respec-
tively. The Mann-Whitney test showed statistically significant 
differences in galectin-1 expression in both groups (p < .001).
VEGF
The expression of VEGF was also observed across all cancer 
cells and stromal elements. In the MELF-negative group, pre-
dominantly moderate expression of this marker was observed 
(Fig. 2C). In the MELF pattern positive group, the expression 
was substantially intense (Fig. 2D). Median VEGF expression 
in the MELF-positive group was 81.4% (58.1%–86.3%) and in 
the group without MELF pattern was 53.0% (47.6%–75.4%). 
The VEGF expression difference between the two groups was sta-
tistically significant (p < .001).
Microvessel density
In various regions of the MELF pattern, a low number of vessels 
was observed. In the group without MELF pattern, vessels were 
situated in small groups, and lymphovascular invasion of EA 
was mostly absent (Fig. 2E). A significant number of microvessels 
was seen in the MELF pattern cases in “hot spots” regions with 
unusual lumens. This was often observed in areas of lymphovascu-
lar invasion (Fig. 2F).
We also measured the number of vessels per mm2 in these 
tissue sections. We found that the median values in MELF-neg-
ative and MELF-positive groups were 101.6 vessels/mm2 (range, 
90.1 to 127.9 vessels/mm2) and 134.5 vessels/mm2 (range, 98.5 
to 156.7 vessels/mm2), respectively, where the latter group 
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showed significantly higher presence than the former (p < .010).
The area of vessels per mm2 was also significantly higher (p < 
0.001) in the stomal changes of the MELF-positive group 
(4,788.3 µm2/mm2; range, 3,087.3 to 5,130.4 µm2/mm2) com-
pared to the group without such specific stromal changes 
(3,037.3 µm2/mm2; range, 2,508.3 to 5,130.4 µm2/mm2).
Correlation analyses
We also analyzed the associations among expressions of the 
Fig. 2. (A) A few positive glandular cells (microcystic, elongated and fragmented [MELF]–negative group). (B) All glandular cells positive for 
galectin-1 expression (MELF-positive group) in endometrioid carcinoma. (C) Positive local areas of cytoplasmic expression of vascular endo-
thelial growth factor (VEGF; MELF-negative group). (D) Intense glandular and cytoplasmic (MELF-positive group) expression of VEGF in 
glands of the endometrioid carcinoma. Low (normal stroma) (E) and increased number of vessels (F) in fibromyxoid stroma situated around 
cancer cells forming gland without lumens. 
MELF pattern, galectin-1, VEGF, area and number of vessels 
per mm2, the outcome of EA (survival or death), and the num-
ber of days of survival (Fig. 3). For instance, galectin-1 demon-
strated a moderate positive correlation with the area of vessels 
per mm2 (p < .001, r = 0.69) and VEGF expression (p < .001, r = 
0.67). Furthermore, galectin-1 expression had a highly positive 
correlation with the outcome of EA (p < .001, r = 0.78) and a high-
ly negative one with the number of days of survival (p < .001, r = 
–0.84). 
A
C
E
B
D
F
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The expression of VEGF had a highly positive correlation with 
the outcome of EA (p < .001, r = 0.85) and a highly negative 
correlation with the number of days of survival (p < .001, r = –0.78). 
The number of vessels per mm2 revealed moderately positive 
correlations with galectin-1 (p < .001, r = 0.54), area of vessels per 
mm2 (p < .001, r = 0.61), and VEGF (p < .001, r = 0.56); a highly 
positive correlation with the outcome of EA (p < .001, r = 0.71); 
and a moderately negative correlation with the number of days 
of survival (p < .001, r = –0.59). 
A highly positive correlation was observed between the area of 
vessels per mm2 and the outcome of EA (p < .001, r = 0.73) and 
VEGF expression (p < .001, r = 0.72). A highly negative correla-
tion was found between the area of vessels per mm2 and the num-
ber of days of survival (p < .001, r = –0.71).
MELF pattern had a slightly negative correlation with the 
number of days of survival (p < .001, r = –0.47) and slightly posi-
tive correlation with galectin-1 expression (p < .001, r = 0.39), the 
area of vessels per mm2 (p < .001, r = 0.36), the outcome of EA 
(p < .001, r = 0.42), and VEGF expression (p < .001, r = 0.39).
Survival analysis
An OS univariate survival analysis was performed, indicating 
that all parameters except age play a role in the survival of pa-
tients with EA (Table 2). However, a multivariate Cox propor-
tional hazard regression analysis of OS revealed that only the 
area of vessels per mm2 (HR, 1.018; 95% CI, 1.002 to 1.033), 
galectin-1 (HR, 1.049; 95% CI, 1.025 to 1.074) and VEGF 
(HR, 1.049; 95% CI, 1.022 to 1.077) play key roles in survival 
irrespective of MELF pattern (Table 2).
A univariate analysis was performed, revealing that all pa-
rameters except age and tumor grade play a role in DFS of patients 
with EA (Table 3). However, our multivariate Cox proportional 
hazard regression analysis demonstrated that only MELF pattern 
(HR, 1.018; 95% CI, 1.002 to 1.033) and galectin-1 expression 
(HR, 1.049; 95% CI, 1.025 to 1.074) were significant predic-
tors of DFS (Table 3).
DISCUSSION
In this study, we investigated the associations between galec-
Table 2. The univariate and multivariate Cox regression analysis results for overall survival
Parameter
Univariable analysis Multivariable analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age 1.012 0.983–1.041 .435 0.992 0.959–1.027 .668
FIGO 1.993 1.361–2.918 < .001 1.304 0.774–2.292 .332
Grade 2.201 1.469–3.297 < .001 1.332 0.776–2.251 .304
Lymphovascular invasion 1.084 1.052–1.118 < .001 1.010 0.942–1.049 .624
Myometrial invasion 1.032 1.011–1.048 < .001 1.028 0.911–1.037 .698
MELF pattern 4.115 2.240–7.558 < .001 1.748 0.870–3.513 .117
No. of vessels 1.036 1.026–1.045 < .001 1.000 0.999–1.000 .623
Area of vessels 1.001 1.001–1,001 < .001 1.018 1.002–1.033 .025
VEGF 1.078 1.058–1.098 < .001 1.049 1.022–1.077 < .001
Galectin-1 1.071 1.054–1089 < .001 1.049 1.025–1.074 < .001
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; MELF, microcystic, elongated and fragmented; VEGF, vascular endothe-
lial growth factor.
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Fig. 3. A correlation plot. Days, number of days of survival from 
surgical treatment to death or end of observation; MELF, microcys-
tic, elongated and fragmented pattern; NoV, number of vessels per 
mm2; Gal-1, galectin-1 expression; AoV, area of vessels per mm2; 
Surv, survival (survival or death); VEGF, vascular endothelial growth 
factor expression.
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tin-1, VEGF, MVD, area of vessels, and survival outcome of EA 
patients with and without a MELF pattern. We identified 49 
patients out of 100 with a MELF pattern and 51 patients with-
out this stromal change who were observed throughout 36 
months from admission to the hospital. In this immunohisto-
chemical study, we demonstrated differential expressions of ga-
lectin-1, VEGF and measurement of MVD in cases with and 
without MELF pattern.
In the last two decades, several galectin family members have 
emerged as versatile modulators of tumor progression. Galec-
tin-1 expression is also frequently reported to be increased in the 
reproductive system as well as the placenta. There is ample evi-
dence that malignant transformation is accompanied by elevated 
galectin-1 levels.12 Jeschke et al.13 reported a statistically signifi-
cant increase of galectin-1 expression in EA with grade 3 and 
stages III/VI (FIGO) compared to grades 1 and 2 and FIGO I/II. 
However, no data are available on the expression of galectin-1 
in EA with different types of stromal changes and survival. In 
our study, we found that galectin-1 expression is higher in EA 
with a MELF pattern compared to cases without a MELF pattern. 
Our observation of positive correlations between galectin-1 ex-
pression and MELF pattern (fibromyxoid changes) and EA out-
come agrees with our previous report and with a report by Sand-
berg et al.,14 in which a correlation was shown between an increased 
galectin-1 expression and fibrotic reaction in tumor progression 
in the stroma in colon cancer. This was accompanied by decreased 
immune cell infiltration, indicating a pro-cancerous role of ga-
lectin-1.14,15 
VEGF was originally identified as a multifunctional cytokine 
in angiogenesis and lymphangiogenesis.16 In cancer angiogenesis, 
VEGF promotes the mobilization of inflammatory cells to the 
tumor site, maintaining the local inflammatory process and in-
ducing the synthesis of proangiogenic factors by endothelial cells, 
platelets, smooth muscle cells, inflammatory cells, fibroblasts, 
and tumor cells.17 This interaction between tumor and stromal 
cells may result in an increased VEGF expression with cancer-
associated fibroblasts being the primary source of VEGF.18 Im-
mature cells of the tumor microenvironment have higher secretion 
of VEGF than mature cells.19 We suggest that this is the reason 
that in our study, MELF pattern stroma had higher expression 
of VEGF than normal stroma in EA. 
Angiogenesis is also known to play crucial roles in the malig-
nant behavior of tumors by increasing oxygen and nutrient supply 
to cancer cells where the neo-vasculatures form an irregular net-
work of capillaries. In addition, such abnormal vasculatures are 
important as a pathway for cancer cell metastasis.20 Accumulated 
evidence indicates that tumor angiogenesis assessed by blood 
MVD is associated with advanced clinicopathological parameters 
and poor prognostic outcomes in different types of cancers.21 
MVD analysis demonstrates high prognostic value in cancers of 
different locations, such as renal, cervical, colorectal and others.22,23 
In MELF pattern positive EA, an increased number and area of 
vessels were observed, which agrees with the previously reported 
study by Joehlin-Price et al.24 on the high frequency of lymph 
node metastasis. 
A moderate correlation between the area of vessels per mm2 
and galectin-1 may be due to the cross-talk between galectin–
glycan interactions and vascular compartments.25 The correla-
tion between galectin-1 and VEGF may be associated with the 
mirroring effects of these proangiogenic factors.26 Galectin-1 
expression in EA may be a prognostic factor in OS of patients, an 
observation that was reported by Wu et al.27 That study reported 
predictive values of this parameter for cholangiocarcinoma, he-
patocellular carcinoma, gingival squamous cell carcinoma, head 
Table 3. The univariate and multivariate Cox regression analysis results for disease-free survival
Parameter
Univariable analysis Multivariable analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age 1.013 0.977–1.049 .495 0.984 0.930–1.042    .584
FIGO 2.330 1.456–3.728 < .001 0.960 0.473–1.948    .910
Grade 1.512 0.928–2.463    .097 0.886 0.409–1.846    .714
Lymphovascular invasion 1.083 1.043–1.124 < .001 0.986 0.940–1.032    .544
Myometrial invasion 1.014 1.012–1.052 < .001 0.978 0.937–1.048    .587
MELF pattern 4.510 1.938–6.342 < .001 3.472 3.109–3.877 < .001
No. of vessels 1.026 1.014–1.038 < .001 1.007 0.989–1.025    .441
Area of vessels 1.002 1.001–1.004 < .001 1.000 0.999–1.000    .431
VEGF 1.049 1.029–1.068 < .001 1.004 0.968–1.043    .813
Galectin-1 1.037 1.023–1.057 < .001 1.050 1.016–1.084    .003
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; MELF, microcystic, elongated and fragmented; VEGF, vascular endothe-
lial growth factor.
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and neck squamous cell carcinoma, renal cell carcinoma, non-
small cell lung cancer, gastric carcinoma and glioblastoma mul-
tiforme.27
VEGF as the main proangiogenic factor and immune sup-
pressive factor of the tumor microenvironment correlates with 
the survival of patients suffering from EA. Goel and Mercurio28 
reported a strong expression of VEGF in endothelial cells in the 
stromal microvessels adjacent to malignant glands, which has 
been reported to be significantly associated with tumor progres-
sion and metastasis. 
A positive correlation between MVD and galectin-1/VEGF 
expression suggested that these parameters play a role in angio-
genesis. Additionally, a highly positive correlation between galec-
tin-1 expression and poor survival, as well as MVD and poor 
survival, suggested that these factors may have a considerable 
predictive role in survival.29 
The presence of a MELF pattern revealed low correlations with 
the above parameters of proangiogenic response in EA. However, 
a low negative correlation of MELF pattern with the number of 
days of survival and a moderate positive correlation with the out-
come of the disease may show that MELF pattern may be an in-
dependent prognostic criterion of patients’ OS. 
The results of multivariate survival analyses showed that MELF 
pattern plays a role in DFS of patients with EA, but not in OS. 
However, our univariate analysis demonstrated a significant effect 
of MELF pattern on both OS and DFS. Previous reports have 
been contradictory on the role of MELF pattern. Sanci et al.6 and 
our previous work reported a positive association, but other 
authors showed that the presence of a MELF pattern plays no 
role in OS. Our study also demonstrated MELF pattern as a pre-
dictive factor of DFS that may be associated with more frequent 
lymph node involvement in cases of MELF pattern presence. 
The absence of influence of FIGO and tumor grade on DFS and 
OS in our study could be associated with homogeneity of the 
comparison groups for these parameters. However, our inclusion 
and exclusion criteria eliminated any potential bias. The system-
atic review of Prodromidou et al.30 revealed that most of the pub-
lished literature describing the role of MELF patterns in patients’ 
survival did not study large cohorts of patients, which may be a 
factor in the inconclusive observations.
Potential limitations of this study are its case-control nature 
with a relatively small volume of cases due to the rare incidence 
of MELF patterns in EA. Despite these limitations, a number of 
study population characteristics mitigated the weaknesses and 
increased the validity of our results. One characteristic was the 
availability of excellent follow-up data. Another was that histo-
pathological analyses made by experienced pathologists. Others 
included that uniform surgical and radiological treatment was 
provided by the same surgical teams in two oncological dispensa-
ries and followed protocols of diagnostics and treatment of onco-
logical diseases of the Republic of Belarus.
In conclusion, this study presented an increase of MVD in areas 
of “hot spots” and angiogenic factors such as VEGF and galectin-1 
in cases of EA with MELF presence. Hence, these biomarkers may 
be used as potential targets for therapy of EA, especially in the 
implementation of personalized medicine in cases with such spe-
cific stromal changes. Our univariate survival analysis revealed 
MELF pattern presence to be an independent predictor in overall 
EA survival, but the multivariate analysis did not show that its 
combination with previously described parameters plays a role in 
survival. Thus, a large case-control study should be conducted to 
confirm our findings.
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